When Emulating a Trial, Do as the Trialists Do: Missteps in Estimating Relative Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster Dose
- PMID: 36041013
- PMCID: PMC9452123
- DOI: 10.1093/cid/ciac700
When Emulating a Trial, Do as the Trialists Do: Missteps in Estimating Relative Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster Dose
Conflict of interest statement
Potential conflicts of interest. K. E. W., L. F., and A. B. are employees and L. F. and A. B. are shareholders of Target RWE. J. K. E. reports grants or contracts from the National Institutes of Health (paid to the author’s institution), consulting fees from PLoS Medicine (paid to the author), and support for attending meetings and/or for travel from the Society for Epidemiologic Research (paid to the author); J. K. E. also had a leadership or fiduciary role on a committee for the Society of Epidemiologic Research (unpaid participation). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment in
-
Reply to Wirth et al.Clin Infect Dis. 2023 Jan 6;76(1):177-178. doi: 10.1093/cid/ciac701. Clin Infect Dis. 2023. PMID: 36041003 No abstract available.
Comment on
-
Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant.Clin Infect Dis. 2022 Dec 19;75(12):2161-2168. doi: 10.1093/cid/ciac328. Clin Infect Dis. 2022. PMID: 35511586 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical